Vaccine adjuvant linked to reduced dementia risk: study
Both Shingrix and Arexvy were associated with a lower dementia risk among older patients.
An adjuvant in shingles and respiratory syncytial virus vaccines could explain their apparent link to reduced dementia risk, a study suggests.
Published in NPJ Vaccines, the study found that both the respiratory syncytial virus (RSV) vaccine Arexvy and the shingles vaccine Shingrix were associated with a lower dementia risk within 18 months of administration, based on 400,000 US health records of patients aged 60 or older.
Compared with receiving a flu vaccine, RSV or shingles vaccinations were associated with a 29% and 18% lower risk of dementia, respectively. Receiving both was associated with a 37% lower risk.
After adjusting for 66 variables — from socioeconomic status to prior herpes infection — flu vaccination showed no association.
